Электронная медицинская библиотека Румедо.

Зарубежные материалы

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Дата публикации 22.10.2020
Автор: Benjamin M. Scirica, M.D., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mosenzon, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D., for the SAVOR-TIMI 53 Steering Committee and Investigators

The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

Подробнее

1226

Зарубежные материалы

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

Дата публикации 22.10.2020
Автор: Tina Ken Schramm, Gunnar Hilmar Gislason, Allan Vaag, Jeppe Nørgaard Rasmussen, Fredrik Folke, Morten Lock Hansen, Emil Loldrup Fosbøl, Lars Køber, Mette Lykke Norgaard, Mette Madsen, Peter Riis Hansen, and Christian Torp-Pedersen

The impact of insulin secretagogues (ISs) on long-term major clinical outcomes in type 2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with all available ISs compared with metformin in a nationwide study.

Подробнее

1465

Зарубежные материалы

High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes

Дата публикации 22.10.2020
Автор: L. J. M. Boonman-de Winter & F. H. Rutten & M. J. M. Cramer & M. J. Landman & A. H. Liem & G. E. H. M. Rutten & A. W. Hoes

Aims/hypothesis The aim of this study was to assess the prevalence of (unknown) heart failure and left ventricular dysfunction in older patients with type 2 diabetes.

Подробнее

1312

Зарубежные материалы

Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death

Дата публикации 22.10.2020
Автор: Lorien S. Dalrymple, MD, MPH1, Ronit Katz, DPhil 2, Bryan Kestenbaum, MD, MS 3, Michael G. Shlipak, MD, MPH4,5, Mark J. Sarnak, MD, MS 6, Catherine Stehman-Breen, MD, MS 7, Stephen Seliger, MD, MS 8, David Siscovick, MD, MPH3,9, Anne B. Newman, MD, MPH10,11, and Linda Fried, MD, MPH10,11,12

In the United States, approximately one in three adults aged 65 years and older has chronic kidney disease (CKD), defined as an eGFR ...

Подробнее

1099

Зарубежные материалы

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Дата публикации 22.10.2020
Автор: S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn, M.G. Silverman, T.A. Zelniker, J.F. Kuder, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, C.T. Ruff, I.A.M. Gause‑Nilsson, M. Fredriksson, P.A. Johansson, A.-M. Langkilde, and M.S. Sabatine, for the DECLARE–TIMI 58 Investigators

The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium – glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.

Подробнее

1048

Зарубежные материалы

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Дата публикации 22.10.2020
Автор: Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl. Biomath., Theresa Devins, Dr.P.H., Odd Erik Johansen, M.D., Ph.D., Hans J. Woerle, M.D., Uli C. Broedl, M.D., and Silvio E. Inzucchi, M.D., for the EMPA-REG OUTCOME Investigators

The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

Подробнее

1190

Зарубежные материалы

Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

Дата публикации 22.10.2020
Автор: Iciar Martín-Timón, Cristina Sevillano-Collantes, Amparo Segura-Galindo, Francisco Javier del Cañizo-Gómez

Diabetes mellitus is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without diabetes, patients with type 2 diabetes mellitus have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular disease.

Подробнее

1252

Зарубежные материалы

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns — NHANES 2007–2012

Дата публикации 22.10.2020
Автор: Bingcao Wu, Kelly Bell, Amy Stanford, David M Kern, Ozgur Tunceli, Suma Vupputuri, Iftekhar Kalsekar, Vincent Willey

To describe the estimated prevalence and temporal trends of chronic kidney disease (CKD) treatment patterns, and the association between CKD and potential factors for type 2 diabetes mellitus (T2DM) in different demographic subgroups.

Подробнее

1063

Зарубежные материалы

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Дата публикации 22.10.2020
Автор: Rury R. Holman, F.Med.Sci., M. Angelyn Bethel, M.D., Robert J. Mentz, M.D., Vivian P. Thompson, M.P.H., Yuliya Lokhnygina, Ph.D., John B. Buse, M.D., Ph.D., Juliana C. Chan, M.D., Jasmine Choi, M.S., Stephanie M. Gustavson, Ph.D., Nayyar Iqbal, M.D., Aldo P. Maggioni, M.D., Steven P. Marso, M.D., Peter Öhman, M.D., Ph.D., Neha J. Pagidipati, M.D., M.P.H., Neil Poulter, F.Med.Sci., Ambady Ramachandran, M.D., Bernard Zinman, M.D., and Adrian F. Hernandez, M.D., M.H.S., for the EXSCEL Study Group*

The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.

Подробнее

1030

Зарубежные материалы

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesd2019

Дата публикации 22.10.2020
Автор: American Diabetes Association

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care.

Подробнее

1486

Зарубежные материалы

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

Дата публикации 22.10.2020
Автор: E.A. Bohula, S.D. Wiviott, D.K. McGuire, S.E. Inzucchi, J. Kuder, K.A. Im, C.L. Fanola, A. Qamar, C. Brown, A. Budaj, A. Garcia‑Castillo, M. Gupta, L.A. Leiter, N.J. Weissman, H.D. White, T. Patel, B. Francis, W. Miao, C. Perdomo, S. Dhadda, M.P. Bonaca, C.T. Ruff, A.C. Keech, S.R. Smith, M.S. Sabatine, and B.M. Scirica, for the CAMELLIA–TIMI 61 Steering Committee and Investigators

Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.

Подробнее

1087

Зарубежные материалы

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Дата публикации 22.10.2020
Автор: Eri T. Kato, MD, MPH, PhD et al

In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...

Подробнее

1160

Статьи

Карманные рекомендации для врачей по ведению пациентов с сахарным диабетом и ожирением

Дата публикации 22.10.2020
Под редакцией: М.В. Шестаковой, академика РАН, д.м.н., проф., директора Института диабета, заместителя директора ФГБУ «Эндокринологический научный центр» по научной работе.

Специализированное издание, предназначенное для медицинских и фармацевтических работников

Подробнее

1059

Зарубежные материалы

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and theEuropeanAssociation for the Study of Diabetes (EASD)

Дата публикации 22.10.2020
Автор: Melanie J. Davies,1,2 David A. D’Alessio,3 Judith Fradkin,4 Walter N. Kernan,5 Chantal Mathieu,6 Geltrude Mingrone,7,8 Peter Rossing,9,10 Apostolos Tsapas,11 Deborah J. Wexler,12,13 and John B. Buse14

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education ...

Подробнее

1100

Зарубежные материалы

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (HHS Public Access)

Дата публикации 22.10.2020
Автор: Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D. for the LEADER Steering Committee on behalf of the LEADER Trial Investigators

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

Подробнее

1564

БИБЛИОТЕКА